IMIDAPRIL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H27N3O6
Molecular Weight	405.4449
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C)C2=O)C(O)=O

InChI

InChIKey=KLZWOWYOHUKJIG-BPUTZDHNSA-N

InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C20H27N3O6
Molecular Weight	405.4449
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugs.com/uk/pdf/leaflet/815031.pdf
Curator's Comment: Description was created based on several sources, including https://www.medicines.org.uk/emc/medicine/31738 http://patient.info/medicine/imidapril-for-high-blood-pressure-tanatril https://www.ncbi.nlm.nih.gov/pubmed/17547476

Imidapril (Tanatril), through its active metabolite imidaprilat, acts as an ACE inhibitor to suppress the conversion of angiotensin I to angiotensin II and thereby reduce total peripheral resistance and systemic blood pressure (BP). In clinical trials, oral imidapril was an effective antihypertensive agent in the treatment of mild to moderate essential hypertension. Some evidence suggests that imidapril also improves exercise capacity in patients with chronic heart failure (CHF) and reduces urinary albumin excretion rate in patients with type 1 diabetes mellitus. Imidapril was well tolerated, with a lower incidence of dry cough than enalapril or benazepril, and is a first choice ACE inhibitor for the treatment of mild to moderate essential hypertension.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin-converting enzyme 97 Target ID: CHEMBL2096989 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18192036 \| https://www.ncbi.nlm.nih.gov/pubmed/8923331	Inhibitor 8297
Angiotensin-converting enzyme 97 Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1322856 \| https://www.ncbi.nlm.nih.gov/pubmed/10480327	Inhibitor 8297		9.9 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567 Sources: https://www.drugs.com/uk/pdf/leaflet/815031.pdf	Primary		Approved 8429	Tanatril Approved Use Tanatril is indicated for the treatment of essential hypertension in adults Launch Date 2007

PubMed

Title	Date	PubMed
[Studies on angiotensin I converting enzyme (ACE) inhibitory effect of imidapril. (I). Inhibition of various tissue ACEs in vitro].	1992 Jul	1322856

Patents

Sample Use Guides

In Vivo Use Guide

Adult: PO Initial: 5 mg once daily at bedtime. Maintenance: 10 mg/day. Max: 20 mg/day. Should be taken on an empty stomach. Take 15 min before meals. However, when initiating therapy, 1st dose should be given at bedtime.

Route of Administration: Oral

In Vitro Use Guide

Imidapril inhibited activity on Angiotensin I converting enzyme (ACE) obtained from pig renal cortex with IC50 9.9uM

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:19:26 GMT 2023` Edited by `admin` on `Fri Dec 15 16:19:26 GMT 2023`
Record UNII	BW7H1TJS22
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IMIDAPRIL

Official Name

English

IMIDAPRIL [MI]

Common Name

English

HIPERTENE

Brand Name

English

imidapril [INN]

Common Name

English

Imidapril [WHO-DD]

Common Name

English

(S)-3-(N-((S)-1-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANYL)-1-METHYL-2-OXOIMIDAZOLINE-4-CARBOXYLIC ACID

Systematic Name

English

Classification Tree Code System Code

WHO-ATC

C09AA16